Meeder Asset Management Inc. lessened its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 75.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 188 shares of the life sciences company’s stock after selling 580 shares during the period. Meeder Asset Management Inc.’s holdings in Illumina were worth $69,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Copper Rock Capital Partners LLC acquired a new position in Illumina during the second quarter worth $10,888,000. Handelsbanken Fonder AB grew its holdings in Illumina by 45.6% during the second quarter. Handelsbanken Fonder AB now owns 60,653 shares of the life sciences company’s stock worth $22,329,000 after acquiring an additional 19,000 shares during the period. Shell Asset Management Co. grew its holdings in Illumina by 5.8% during the first quarter. Shell Asset Management Co. now owns 24,863 shares of the life sciences company’s stock worth $7,725,000 after acquiring an additional 1,369 shares during the period. Diversified Trust Co acquired a new position in Illumina during the first quarter worth $1,544,000. Finally, Hartford Investment Management Co. grew its holdings in Illumina by 0.8% during the second quarter. Hartford Investment Management Co. now owns 18,141 shares of the life sciences company’s stock worth $6,679,000 after acquiring an additional 148 shares during the period. 92.09% of the stock is currently owned by hedge funds and other institutional investors.
In related news, CEO Francis A. Desouza sold 3,000 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $301.25, for a total transaction of $903,750.00. Following the transaction, the chief executive officer now directly owns 64,200 shares in the company, valued at $19,340,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jay T. Flatley sold 3,300 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $376.50, for a total value of $1,242,450.00. Following the transaction, the director now owns 272,616 shares in the company, valued at $102,639,924. The disclosure for this sale can be found here. Insiders have sold 60,458 shares of company stock worth $19,329,754 over the last quarter. 0.38% of the stock is currently owned by company insiders.
ILMN opened at $282.79 on Wednesday. The company has a quick ratio of 6.10, a current ratio of 6.79 and a debt-to-equity ratio of 0.42. The firm has a market cap of $41.34 billion, a P/E ratio of 49.44, a PEG ratio of 2.61 and a beta of 1.10. Illumina, Inc. has a 52 week low of $268.62 and a 52 week high of $380.76. The business’s fifty day simple moving average is $298.93 and its 200 day simple moving average is $315.16.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. Illumina had a return on equity of 21.73% and a net margin of 27.56%. The business had revenue of $838.00 million for the quarter, compared to analyst estimates of $835.12 million. During the same quarter last year, the company earned $1.43 earnings per share. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. As a group, equities analysts expect that Illumina, Inc. will post 6.04 EPS for the current fiscal year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: How do buyers and sellers choose a strike price?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.